Indegene plans to hire up to 2,500 in FY22
Premium
2 min read
Read Full Story
BENGALURU :
Tech-enabled healthcare solutions company Indegene is expanding its operations by hiring specialized talent as well as through specific acquisitions that complement its business.
The Bengaluru-based company plans to hire up to 2,500 people this fiscal year across offices, out of which about 2,000 will be based in India, 200 in North America, 100 in Japan and China, and the remaining in Europe. It has a total headcount of about 4,000 employees globally.
MORE FROM THIS SECTIONSee All
Premium Premium
Premium Premium
Premium Premium
Premium Premium Centre issues rules for second PLI plan for pharma wort ..
Read more about Covid: China learnings help Indegene save lives of its employees in India on Business Standard. At a time when the second wave of the Covid-19 pandemic has wreaked havoc across the country, Indegene s practices can become a template for the corporate industry to manage the pandemic
Manish Gupta, co-founder and CEO, Indegene; image credit: @Indegene via Facebook
Synopsis
Through its 20-year journey, Indegene has developed deep domain expertise, a robust database, and strong relations with healthcare practitioners, enabling it to provide customised and efficient technology-driven solutions to pharmaceutical companies. With the pandemic fast-tracking tech adoption, Indegene is poised to harness the opportunity of driving the digital transformation of the life-sciences industry globally.
It is well-known that it takes years and billions of dollars for a pharmaceutical company to develop an innovative drug. But commercialisation of drugs is also an investment-heavy affair. For example, selling, informational, and administrative expenses of Pfizer, one of the largest pharma companies in the world, were 27.7% of its revenue of USD42 billion in 2020. These expenses include but are not limited to the company’s spend on marketing and
Indegene and ConTIPI Medical Ltd Partner to Bring Innovative Disposable Non-surgical Device to Market to Help Women Suffering from Pelvic Organ Prolapse (POP) Font : A-A+
PRINCETON, N.J., March 03, 2021 (GLOBE NEWSWIRE) Indegene, a global enterprise healthtech solutions company and ConTIPI Medical Ltd, an innovator in the field of providing non-surgical and disposable solutions for women with various pelvic floor disfunctions, today announced a partnership to bring a new device to the market to help women suffering from Pelvic Organ Prolapse (POP). The US FDA states that POP occurs when the pelvic floors tissues and muscles can no longer support its organs. This causes a drop or prolapse of the pelvic organs from their normal position into the vagina and even outside the body. POP is prevalent in approximately 54 million American women over 20 years old
(1)
PRINCETON, N.J., March 03, 2021 (GLOBE NEWSWIRE) Indegene, a global enterprise healthtech solutions company and ConTIPI Medical Ltd, an innovator in the field of providing non-surgical and disposable solutions for women with various pelvic floor disfunctions, today announced a partnership to bring a new device to the market to help women suffering from Pelvic Organ Prolapse (POP).
The US FDA states that POP occurs when the pelvic floor s tissues and muscles can no longer support its organs. This causes a drop or prolapse of the pelvic organs from their normal position into the vagina and even outside the body. POP is prevalent in approximately 54 million American women over 20 years old